peptide therapy explained FAQ

Verify peptide stability first. If the formulation wasn't stored properly or exceeds its reconstitution date, degraded peptide loses activity. Contact the compounding source to confirm batch potency and storage conditions. Two weeks represents the minimum timeframe for visible symptom change. Cytokine suppression occurs within days, but tissue remodeling and inflammation resolution require 3–4 weeks. If the underlying trigger remains active (ongoing microbial colonization, continued mechanical trauma), KPV will reduce inflammation but won't eliminate the condition. Add appropriate antimicrobial treatment or identify environmental triggers before concluding KPV ineffectiveness.

Cytokine levels rebound within 48–72 hours of stopping KPV. Missing 3–4 days resets progress. Inflammation may return to baseline before resuming treatment. Resume twice-daily application immediately and expect a 7–10 day lag before regaining symptom control. Consistent dosing matters more than high-dose intermittent application. Twice-daily low-dose KPV maintains receptor occupancy better than sporadic high-concentration use.

Irritation typically stems from the carrier vehicle. Not the peptide itself. DMSO-based formulations cause stinging and temporary redness in 30–40% of users, especially on inflamed or broken skin. Switch to a liposomal or emulsion-based carrier without alcohol or DMSO. If irritation persists with multiple formulations, consider subcutaneous administration instead. Injection-site discomfort resolves within 24 hours, whereas topical irritation can compound existing scalp sensitivity.

Discard it. A single 8–12 hour ambient temperature exposure (20–25°C) degrades approximately 15–25% of peptide potency, and there's no reliable field test to measure remaining bioavailability. Injecting degraded peptide doesn't cause harm, but it introduces uncontrolled variables into your research data. You're dosing an unknown concentration, which makes results uninterpretable. If the vial was out for fewer than 2 hours and the room temperature was below 22°C, refrigerate it immediately and use it within 7 days, noting the storage deviation in your research log for downstream analysis.

Resume at the standard dose. Do not double-dose to compensate. CJC-1295's extended half-life means plasma levels decline gradually, so missing 3 days won't drop you to baseline. Ipamorelin's short half-life means pulsatile stimulation stops immediately, but the cumulative IGF-1 elevation built over prior weeks persists for 7–10 days. The primary effect of a 3-day gap is loss of the acute nocturnal GH pulse, not collapse of long-term anabolic signaling. Resume evening dosing and continue the protocol without extending the study duration.

Do not inject. Properly reconstituted CJC Ipa Blend should be clear and colorless. Cloudiness indicates aggregation of denatured peptide fragments or bacterial contamination. Particulates suggest incomplete dissolution (which resolves with gentle swirling, not shaking) or stopper debris from improper needle insertion. If swirling doesn't clear the solution within 30 seconds, discard the vial. Aggregated peptides lose receptor binding affinity and can trigger immune responses in research models, compromising study endpoints.

Contact the supplier immediately and request a replacement or temperature log verification. Lyophilised peptides can tolerate brief temperature excursions (up to 30°C for 24–48 hours) with minimal degradation, but prolonged exposure above 35°C denatures the protein irreversibly. If gel packs are still cold or cool to the touch, the peptide is likely intact. If gel packs are warm and the package sat in a hot mailbox for hours, potency is compromised. Reputable suppliers like Real Peptides include temperature indicators or offer expedited cold-chain shipping during warm months to prevent this scenario.